242 related articles for article (PubMed ID: 31894749)
1. Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials.
Relitti N; Saraswati AP; Federico S; Khan T; Brindisi M; Zisterer D; Brogi S; Gemma S; Butini S; Campiani G
Curr Top Med Chem; 2020; 20(6):433-457. PubMed ID: 31894749
[TBL] [Abstract][Full Text] [Related]
2. Potential Telomere-Related Pharmacological Targets.
Berei J; Eckburg A; Miliavski E; Anderson AD; Miller RJ; Dein J; Giuffre AM; Tang D; Deb S; Racherla KS; Patel M; Vela MS; Puri N
Curr Top Med Chem; 2020; 20(6):458-484. PubMed ID: 31916516
[TBL] [Abstract][Full Text] [Related]
3. Agents that target telomerase and telomeres.
Raymond E; Sun D; Chen SF; Windle B; Von Hoff DD
Curr Opin Biotechnol; 1996 Dec; 7(6):583-91. PubMed ID: 8939642
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
Raymond E; Faivre S; Dieras V; Von Hoff D
Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
[TBL] [Abstract][Full Text] [Related]
5. Novel anticancer therapeutics targeting telomerase.
Ruden M; Puri N
Cancer Treat Rev; 2013 Aug; 39(5):444-56. PubMed ID: 22841437
[TBL] [Abstract][Full Text] [Related]
6. Crossroads of telomere biology and anticancer drug discovery.
Seimiya H
Cancer Sci; 2020 Sep; 111(9):3089-3099. PubMed ID: 32579791
[TBL] [Abstract][Full Text] [Related]
7. Anticancer therapy targeting telomeres and telomerase : current status.
Parkinson EK; Minty F
BioDrugs; 2007; 21(6):375-85. PubMed ID: 18020621
[TBL] [Abstract][Full Text] [Related]
8. Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors.
Saraswati AP; Relitti N; Brindisi M; Gemma S; Zisterer D; Butini S; Campiani G
Drug Discov Today; 2019 Jul; 24(7):1370-1388. PubMed ID: 31136800
[TBL] [Abstract][Full Text] [Related]
9. Telomeres, telomerase and cancer: is the magic bullet real?
Sharma HW; Maltese JY; Zhu X; Kaiser HE; Narayanan R
Anticancer Res; 1996; 16(1):511-5. PubMed ID: 8615664
[TBL] [Abstract][Full Text] [Related]
10. Oligonucleotides Targeting Telomeres and Telomerase in Cancer.
Schrank Z; Khan N; Osude C; Singh S; Miller RJ; Merrick C; Mabel A; Kuckovic A; Puri N
Molecules; 2018 Sep; 23(9):. PubMed ID: 30189661
[TBL] [Abstract][Full Text] [Related]
11. Telomere maintenance as a target for drug discovery.
Sekaran V; Soares J; Jarstfer MB
J Med Chem; 2014 Feb; 57(3):521-38. PubMed ID: 24053596
[TBL] [Abstract][Full Text] [Related]
12. Telomerase inhibitors: a patent review (2010-2015).
Man RJ; Chen LW; Zhu HL
Expert Opin Ther Pat; 2016 Jun; 26(6):679-88. PubMed ID: 27104627
[TBL] [Abstract][Full Text] [Related]
13. Telomerase: a potential therapeutic target for cancer.
Fletcher TM
Expert Opin Ther Targets; 2005 Jun; 9(3):457-69. PubMed ID: 15948667
[TBL] [Abstract][Full Text] [Related]
14. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.
Jafri MA; Ansari SA; Alqahtani MH; Shay JW
Genome Med; 2016 Jun; 8(1):69. PubMed ID: 27323951
[TBL] [Abstract][Full Text] [Related]
15. Telomeres and telomerase: Pharmacological targets for new anticancer strategies?
Pendino F; Tarkanyi I; Dudognon C; Hillion J; Lanotte M; Aradi J; Ségal-Bendirdjian E
Curr Cancer Drug Targets; 2006 Mar; 6(2):147-80. PubMed ID: 16529544
[TBL] [Abstract][Full Text] [Related]
16. How to inhibit telomerase activity for cancer therapy.
Kyo S; Inoue M
Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):613-26. PubMed ID: 12678728
[TBL] [Abstract][Full Text] [Related]
17. Telomerase inhibitors for the treatment of cancer: the current perspective.
Perry PJ; Arnold JR; Jenkins TC
Expert Opin Investig Drugs; 2001 Dec; 10(12):2141-56. PubMed ID: 11772310
[TBL] [Abstract][Full Text] [Related]
18. Telomerase-Targeted Cancer Immunotherapy.
Mizukoshi E; Kaneko S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013796
[TBL] [Abstract][Full Text] [Related]
19. Telomere biology of pediatric cancer.
Tabori U; Dome JS
Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
[TBL] [Abstract][Full Text] [Related]
20. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
